BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Reckitt Benckiser Plc (RB.L) Completes Acquisition of Adams Respiratory Therapeutics


1/30/2008 8:45:52 AM

CHESTER, N.J. and SLOUGH, England, Jan. 30 /PRNewswire/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") today announced the successful completion of its acquisition of Adams Respiratory Therapeutics, Inc. ("Adams") through a cash tender offer followed by a short- form merger of its indirect wholly owned subsidiary, Twickenham Inc., with and into Adams. As a result of this acquisition, Adams becomes an indirect wholly owned subsidiary of Reckitt Benckiser.

At the effective time of the merger, all outstanding shares of Adams common stock not validly tendered and accepted for payment in the tender offer were converted into the right to receive US$60.00 per share in cash (the same price paid in the tender offer), without interest and subject to applicable withholding of taxes. American Stock Transfer & Trust Company, acting as the paying agent for the merger, will mail to the remaining former shareholders of Adams materials necessary to exchange their former Adams shares for such payment. As a result of the merger, Adams shares will be delisted and cease to trade on the NASDAQ Global Select Market.

Notes for Editors

Reckitt Benckiser is a world leader in household cleaning, health and personal care. The Company is truly global, with over 60 operating companies and some 43 manufacturing facilities worldwide and has sales in 180 countries. Reckitt Benckiser employs 22,000 people around the world. Amongst the Company's leading brands in household are Lysol, the world leader in disinfecting cleaning, Calgonit & Finish & Electrasol, the world leaders in automatic dishwashing, Woolite, world leader in fine fabrics, Vanish & Spray'n Wash, world leaders in fabric treatment, Airwick and Mortein, both No.2 brands in air care and pest control respectively. In Health & Personal Care (25% of net revenues), leading brand positions include Veet, the world number one depilatory and Dettol the world's leading antiseptic, Nurofen, the leading European analgesic, Strepsils, world number one in medicated sore throat, Gaviscon the No.1 gastro intestinal remedy in UK and Lemsip the UK No.1 in cold/flu remedies.

Reckitt Benckiser is headquartered in Slough just outside London, UK and is listed on the London stock exchange. Reckitt Benckiser had net revenues of 4.92bn pounds, operating profit of 910m pounds, and net income of 674m pounds in 2006.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

CONTACT: Mark Wilson, Corporate Controller and Acting Head of Investor
Relations, investor queries, or Fiona Fong, Head of Corporate
Communications, press queries, both of Reckitt Benckiser, +44 0 1753 217
800; Susan Gilchrist of Brunswick, +44 0 207 404 5959, or Cindy Leggett
Flynn of Brunswick New York, +1-212-333-3810; Janet M. Barth, SVP Investor
Relations & Corporate Communications, +1-908-879-2428, or Faith
Pomeroy-Ward, Sr. Manager Investor Relations & Corporate Communications,
+1-908-879-1418, both of Adams Respiratory Therapeutics

Web site: http://www.adamsrt.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES